Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Susan H. Alexander net worth and biography

Susan Alexander Biography and Net Worth

EVP of Biogen

Susan H. Alexander is Executive Vice President, Chief Legal Officer and Secretary of Biogen, and has served on the Executive Committee since 2006. Prior to that, from 2006 to December 2011, Ms. Alexander served as our Executive Vice President, General Counsel and Corporate Secretary. From 2003 to January 2006, Ms. Alexander served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corporation, a biopharmaceutical services company. From 2001 to 2003, Ms. Alexander served as General Counsel of IONA Technologies, a software company. From 1995 to 2001, Ms. Alexander served as Counsel at Cabot Corporation, a specialty chemicals and performance materials company. Prior to that, Ms. Alexander was a partner at the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne. Ms. Alexander received her B.A. from Wellesley College and her J.D. from Boston University School of Law.

What is Susan H. Alexander's net worth?: The estimated net worth of Susan H. Alexander is at least $5.77 million as of October 27th, 2022. Ms. Alexander owns 39,396 shares of Biogen stock worth more than $5,770,332 as of December 21st. This net worth estimate does not reflect any other assets that Ms. Alexander may own. Additionally, Ms. Alexander receives a salary of $1,950,000.00 as EVP at Biogen. Learn More about Susan H. Alexander's net worth.
How old is Susan H. Alexander?: Ms. Alexander is currently 67 years old. There are 7 older executives and no younger executives at Biogen. Learn More on Susan H. Alexander's age.
What is Susan H. Alexander's salary?: As the EVP of Biogen Inc., Ms. Alexander earns $1,950,000.00 per year. There are 2 executives that earn more than Ms. Alexander. The highest earning executive at Biogen is Mr. Christopher A. Viehbacher, President, CEO & Director, who commands a salary of $4,070,000.00 per year. Learn More on Susan H. Alexander's salary.
How do I contact Susan H. Alexander?: The corporate mailing address for Ms. Alexander and other Biogen executives is 225 BINNEY STREET, CAMBRIDGE MA, 02142. Biogen can also be reached via phone at (617) 679-2000 and via email at [email protected]. Learn More on Susan H. Alexander's contact information.
Has Susan H. Alexander been buying or selling shares of Biogen?: Susan H. Alexander has not been actively trading shares of Biogen in the last ninety days. Most recently, Susan H. Alexander sold 5,532 shares of the business's stock in a transaction on Thursday, October 27th. The shares were sold at an average price of $280.70, for a transaction totalling $1,552,832.40. Following the completion of the sale, the executive vice president now directly owns 39,396 shares of the company's stock, valued at $11,058,457.20. Learn More on Susan H. Alexander's trading history.
Who are Biogen's active insiders?: Biogen's insider roster includes Susan Alexander (EVP), Brian Posner (Director), Eric Rowinsky (Director), Alfred Sandrock (insider), Priya Singhal (Insider), and Michel Vounatsos (CEO). Learn More on Biogen's active insiders.
Are insiders buying or selling shares of Biogen?: During the last twelve months, Biogen insiders bought shares 1 times. They purchased a total of 455 shares worth more than $101,255.70. During the last twelve months, insiders at the biotechnology company sold shares 5 times. They sold a total of 1,313 shares worth more than $290,048.92. The most recent insider tranaction occured on September, 3rd when insider Priya Singhal sold 431 shares worth more than $88,018.82. Insiders at Biogen own 0.2% of the company. Learn More about insider trades at Biogen.
Information on this page was last updated on 9/3/2024.

Susan H. Alexander Insider Trading History at Biogen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/27/2022	Sell	5,532	$280.70	$1,552,832.40	39,396
7/25/2017	Sell	4,974	$290.01	$1,442,509.74	22,258
7/19/2017	Sell	7,758	$285.00	$2,211,030.00	27,232

Susan H. Alexander Buying and Selling Activity at Biogen

Biogen Company Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $146.47

$145.07

$147.85

50 Day Range

MA: $167.48

$146.47

$191.56

2 Week Range

Now: $146.47

$145.07

$268.30

Volume

5,775,622 shs

Average Volume

1,216,867 shs

Market Capitalization

$21.34 billion

P/E Ratio

13.23

Dividend Yield

N/A

Beta

N/A

Most People Are Dead Wrong.

From Brownstone Research | Ad

I call it my AI Retirement Playbook. I recommend you check it out now.

Susan Alexander Biography and Net Worth

What is Susan H. Alexander's net worth?

How old is Susan H. Alexander?

What is Susan H. Alexander's salary?

How do I contact Susan H. Alexander?

Has Susan H. Alexander been buying or selling shares of Biogen?

Who are Biogen's active insiders?

Are insiders buying or selling shares of Biogen?